Top

Published in:

01-10-2013 | Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

From Physiology to Pharmacy: Developments in the Pathogenesis and Treatment of Recurrent Urinary Tract Infections

Authors: Jennifer A. Silverman, Henry L. Schreiber IV, Thomas M. Hooton, Scott J. Hultgren

Published in: Current Urology Reports | Issue 5/2013

Abstract

Urinary tract infections (UTIs) are common, and over half of women report having had at least one in their lifetime. Nearly a third of these women experience recurrent UTI episodes, but the mechanisms of these recurrences are not fully elucidated. Frequent use of antimicrobials for treatment and prevention of UTIs and other infections has contributed to the evolution of multidrug-resistant microorganisms globally. This is a looming worldwide crisis that has created an urgent need for novel strategies for the treatment and prevention of UTIs. Furthering our understanding of the mechanisms of recurrent UTIs, from both host and bacterial perspectives, will be paramount in developing targeted management strategies. In this review, we discuss recent findings regarding recurrent UTIs in women, including progress in our understanding of the mechanisms of recurrence as well as emerging treatments.

Foxman B, Barlow R, D'Arcy H, et al. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000;10:509–15.PubMedCrossRef

Griebling TL: Urinary Tract Infection in Women. In: Litwin MS, Saigal CS, editors. Urologic diseases in America. US DHHS, PHS, NIH, NIDDKD. Washington DC: US GPO; 2007. 587–620.

Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7:653–60.PubMedCrossRef

Hung CS, Dodson KW, Hultgren SJ. A murine model of urinary tract infection. Nat Protoc. 2009;4:1230–43.PubMedCrossRef

Hannan TJ, Totsika M, Mansfield KJ, et al. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev. 2012;36:616–48.PubMedCrossRef

Thumbikat P, Berry RE, Schaeffer AJ, Klumpp DJ. Differentiation-induced uroplakin III expression promotes urothelial cell death in response to uropathogenic E. coli. Microbes Infect. 2009;11:57–65.PubMedCrossRef

Thumbikat P, Berry RE, Zhou G, et al. Bacteria-induced uroplakin signaling mediates bladder response to infection. PLoS Pathog. 2009;5:e1000415.PubMedCrossRef

Song J, Bishop BL, Li G, et al. TLR4-initiated and cAMP-mediated abrogation of bacterial invasion of the bladder. Cell Host Microbe. 2007;1:287–98.PubMedCrossRef

Anderson GG, Palermo JJ, Schilling JD, et al. Intracellular bacterial biofilm-like pods in urinary tract infections. Science. 2003;301:105–7.PubMedCrossRef

10.

Mysorekar IU, Hultgren SJ. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci USA. 2006;103:14170–5.PubMedCrossRef

11.

• Hannan TJ, Mysorekar IU, Hung CS, et al. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog. 2010;6:e1001042. This important work identified a connection between inflammation and UTI outcome in mice. More severe inflammatory responses correlated with a predisposition for chronic UTI, suggesting the immune response to an initial UTI affects the likelihood of experiencing future UTIs.PubMedCrossRef

12.

Schwartz DJ, Chen SL, Hultgren SJ, Seed PC. Population dynamics and niche distribution of uropathogenic Escherichia coli during acute and chronic urinary tract infection. Infect Immun. 2011;79:4250–9.PubMedCrossRef

13.

Walters MS, Lane MC, Vigil PD, et al. Kinetics of uropathogenic Escherichia coli metapopulation movement during urinary tract infection. MBio. 2012; 3.

14.

Hunstad DA, Justice SS. Intracellular lifestyles and immune evasion strategies of uropathogenic Escherichia coli. Annu Rev Microbiol. 2010;64:203–21.PubMedCrossRef

15.

Nielubowicz GR, Mobley HL. Host-pathogen interactions in urinary tract infection. Nat Rev Urol. 2010;7:430–41.PubMedCrossRef

16.

• Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103–20. This reference discusses the emerging worldwide problem of antimicrobial resistance and current empiric treatment strategies for uncomplicated cystitis and pyelonephritis.PubMedCrossRef

17.

Zhanel GG, Hisanaga TL, Laing NM, et al. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents. 2005;26:380–8.PubMedCrossRef

18.

Schito GC, Naber KG, Botto H, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009;34:407–13.PubMedCrossRef

19.

Bonkat G, Muller G, Braissant O, et al. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates. World J Urol. 2013.

20.

Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol. 2000;151:1194–205.PubMedCrossRef

21.

Ikaheimo R, Siitonen A, Heiskanen T, et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis. 1996;22:91–9.PubMedCrossRef

22.

Hooton TM. Clinical practice. Uncomplicated urinary tract infection. New Engl J Med. 2012;366:1028–37.PubMedCrossRef

23.

Yamamoto S, Tsukamoto T, Terai A, et al. Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by Escherichia coli. J Urol. 1997;157:1127–9.PubMedCrossRef

24.

Czaja CA, Stamm WE, Stapleton AE, et al. Prospective cohort study of microbial and inflammatory events immediately preceding Escherichia coli recurrent urinary tract Infection in women. J Infect Dis. 2009;200:528–36.PubMedCrossRef

25.

Ejrnaes K, Sandvang D, Lundgren B, et al. Pulsed-field gel electrophoresis typing of Escherichia coli strains from samples collected before and after pivmecillinam or placebo treatment of uncomplicated community-acquired urinary tract infection in women. J Clin Microbiol. 2006;44:1776–81.PubMedCrossRef

26.

Foxman B, Zhang L, Tallman P, et al. Virulence characteristics of Escherichia coli causing first urinary tract infection predict risk of second infection. J Infect Dis. 1995;172:1536–41.PubMedCrossRef

27.

Kärkkäinen U, Ikaheimo R, Katila M-L, Siitonen A. Recurrence of urinary tract infections in adult patients with community-acquired pyelonephritis caused by E. coli: a 1-year follow-up. Scand J Infect Dis. 2000;32:495–9.PubMedCrossRef

28.

Kõljalg S, Truusalu K, Vainumäe I, et al. Persistence of Escherichia coli clones and phenotypic and genotypic antibiotic resistance in recurrent urinary tract infections in childhood. J Clin Microbiol. 2009;47:99–105.PubMedCrossRef

29.

Kunin CM. A ten-year study of bacteriuria in schoolgirls: final report of bacteriologic, urologic, and epidemiologic findings. J Infect Dis. 1970;122:382–93.PubMedCrossRef

30.

Luo Y, Ma Y, Zhao Q, et al. Similarity and divergence of phylogenies, antimicrobial susceptibilities, and virulence factor profiles of Escherichia coli isolates causing recurrent urinary tract infections that persist or result from reinfection. J Clin Microbiol. 2012;50:4002–7.PubMedCrossRef

31.

McGeachie J. Recurrent infection of the urinary tract: reinfection or recrudescence? Brit Med J. 1966;1:952–4.PubMedCrossRef

32.

Pryles CV, Glagovsky A. Serological characterization of Escherichia coli. study in acute and recurrent urinary tract infections in infants and children. Pediatrics. 1965;36:219–24.PubMed

33.

Russo TA, Stapleton A, Wenderoth S, et al. Chromosomal restriction fragment length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infections in young women. J Infect Dis. 1995;172:440–5.PubMedCrossRef

34.

Skjøt-Rasmussen L, Hammerum AM, Jakobsen L, et al. Persisting clones of Escherichia coli isolates from recurrent urinary tract infection in men and women. J Med Microbiol. 2011;60:550–4.PubMedCrossRef

35.

Winberg J, Andersen HJ, Bergström T, et al. Epidemiology of symptomatic urinary tract infection in childhood. Acta Paediatr. 1974;63:1–20.CrossRef

36.

• Wang C, Symington JW, Ma E, et al. Estrogenic modulation of uropathogenic Escherichia coli infection pathogenesis in a murine menopause model. Infect Immun. 2013;81:733–9. This paper establishes an ovariectomized mouse model to mimic menopause, finding that more QIRs are present in ovariectomized mice and observing a protective effect of estrogen therapy.PubMedCrossRef

37.

Foxman B. Urinary tract infection in postmenopausal women. Curr Infect Dis Rep. 1999;1:367–70.PubMedCrossRef

38.

•• Chen SL, Wu M, Henderson JP, et al. Genomic diversity and fitness of E. coli strains recovered from the intestinal and urinary tracts of women with recurrent urinary tract infection. Sci Transl Med. 2013;5:184ra160. This work describes a seminal finding: E. coli isolates found in the urinary tract are not necessarily less fit than those found in the intestine, and UTI recurrences could be due to the introduction of more fit strains of E. coli than the ones that caused previous episodes. This paper calls attention to the need to investigate the gut as a reservoir for UPEC.CrossRef

39.

Nowrouzian F, Hesselmar B, Saalman R, et al. Escherichia coli in infants' intestinal microflora: colonization rate, strain turnover, and virulence gene carriage. Pediatr Res. 2003;54:8–14.PubMedCrossRef

40.

Beerepoot MA, ter Riet G, Nys S, et al. Cranberries vs antibiotics to prevent urinary tract infections: a randomized double-blind noninferiority trial in premenopausal women. Arch Intern Med. 2011;171:1270–8.PubMedCrossRef

41.

Cunha BA. Prophylaxis for recurrent urinary tract infections: nitrofurantoin, not trimethoprim-sulfamethoxazole or cranberry juice. Arch Intern Med. 2012;172:82. author reply 82–83.PubMedCrossRef

42.

McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. J Antimicrob Chemother. 1994;33(Suppl A):23–30.PubMedCrossRef

43.

American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;2012(60):616–31.CrossRef

44.

Blango MG, Mulvey MA. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother. 2010;54:1855–63.PubMedCrossRef

45.

Chen CS, Ho DR, Chang PJ, et al. Urine post equivalent daily cranberry juice consumption may opsonize uropathogenicity of Escherichia coli. J Infect Chemother. 2013.

46.

Sobota AE. Inhibition of bacterial adherence by cranberry juice: potential use for the treatment of urinary tract infections. J Urol. 1984;131:1013–6.PubMed

47.

Gupta K, Chou MY, Howell A, et al. Cranberry products inhibit adherence of p-fimbriated Escherichia coli to primary cultured bladder and vaginal epithelial cells. J Urol. 2007;177:2357–60.PubMedCrossRef

48.

Barbosa-Cesnik C, Brown MB, Buxton M, et al. Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. Clin Infect Dis. 2011;52:23–30.PubMedCrossRef

49.

Takahashi S, Hamasuna R, Yasuda M, et al. A randomized clinical trial to evaluate the preventive effect of cranberry juice (UR65) for patients with recurrent urinary tract infection. J Infect Chemother. 2013;19:112–7.PubMedCrossRef

50.

Wang CH, Fang CC, Chen NC, et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172:988–96.PubMedCrossRef

51.

Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10, CD001321.PubMed

52.

• Bleidorn J, Gagyor I, Kochen MM, et al. Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection?--results of a randomized controlled pilot trial. BMC Med. 2010;8:30. This is a small pilot trial that raises the intriguing possibility that anti-inflammatories may have a role in the treatment of acute cystitis.PubMedCrossRef

53.

Schwartz DJ, Hultgren SJ. Uropathogenic Escherichia coli Virulence and Gene Regulation. In: Darwin AJ, Vasil ML, editors. Regulation of bacterial virulence. Washington, DC: ASM Press; 2012. p. 135–55.

54.

Spurbeck RR, Stapleton AE, Johnson JR, et al. Fimbrial profiles predict virulence of uropathogenic Escherichia coli strains: contribution of ygi and yad fimbriae. Infect Immun. 2011;79:4753–63.PubMedCrossRef

55.

Hung CS, Bouckaert J, Hung D, et al. Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Mol Microbiol. 2002;44:903–15.PubMedCrossRef

56.

Mulvey MA, Lopez-Boado YS, Wilson CL, et al. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science. 1998;282:1494–7.PubMedCrossRef

57.

Wu XR, Sun TT, Medina JJ. In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. Proc Natl Acad Sci USA. 1996;93:9630–5.PubMedCrossRef

58.

Bouckaert J, Berglund J, Schembri M, et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol. 2005;55:441–55.PubMedCrossRef

59.

Han Z, Pinkner JS, Ford B, et al. Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem. 2010;53:4779–92.PubMedCrossRef

60.

Han Z, Pinkner JS, Ford B, et al. Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J Med Chem. 2012;55:3945–59.PubMedCrossRef

61.

•• Cusumano CK, Pinkner JS, Han Z, et al. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med. 2011;3:109ra115. This work describes optimization and murine bioavailability studies of small anti-adhesion molecules. Importantly, these molecules could treat and prevent UTI, and had a synergistic effect when combined with TMP/SMX treatment.PubMedCrossRef

62.

Schwardt O, Rabbani S, Hartmann M, et al. Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists. Bioorg Med Chem. 2011;19:6454–73.PubMedCrossRef

63.

Jiang X, Abgottspon D, Kleeb S, et al. Antiadhesion therapy for urinary tract infections–a balanced PK/PD profile proved to be key for success. J Med Chem. 2012;55:4700–13.PubMedCrossRef

64.

Scharenberg M, Schwardt O, Rabbani S, Ernst B. Target selectivity of FimH antagonists. J Med Chem. 2012;55:9810–6.PubMedCrossRef

65.

Pinkner JS, Remaut H, Buelens F, et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci USA. 2006;103:17897–902.PubMedCrossRef

66.

Chorell E, Pinkner JS, Bengtsson C, et al. Design and synthesis of fluorescent pilicides and curlicides: bioactive tools to study bacterial virulence mechanisms. Chemistry. 2012;18:4522–32.PubMedCrossRef

67.

Aberg V, Fallman E, Axner O, et al. Pilicides regulate pili expression in E. coli without affecting the functional properties of the pilus rod. Mol Biosyst. 2007;3:214–8.PubMedCrossRef

68.

Cegelski L, Pinkner JS, Hammer ND, et al. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol. 2009;5:913–9.PubMedCrossRef

69.

• Brumbaugh AR, Mobley HL. Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vaccines. 2012;11:663–76. This work is an excellent, comprehensive review of advancements made in UTI vaccines.PubMedCrossRef

70.

Alteri CJ, Hagan EC, Sivick KE, et al. Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLoS Pathog. 2009;5:e1000586.PubMedCrossRef

71.

Wieser A, Romann E, Magistro G, et al. A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice. Infect Immun. 2010;78:3432–42.PubMedCrossRef

72.

Langermann S, Palaszynski S, Barnhart M, et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science. 1997;276:607–11.PubMedCrossRef

73.

Poggio TV, La Torre JL, Scodeller EA. Intranasal immunization with a recombinant truncated FimH adhesin adjuvanted with CpG oligodeoxynucleotides protects mice against uropathogenic Escherichia coli challenge. Can J Microbiol. 2006;52:1093–102.PubMedCrossRef

74.

Langermann S, Mollby R, Burlein JE, et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis. 2000;181:774–8.PubMedCrossRef

75.

Karam MR, Oloomi M, Mahdavi M, et al. Assessment of immune responses of the flagellin (FliC) fused to FimH adhesin of uropathogenic Escherichia coli. Mol Immunol. 2013;54:32–9.PubMedCrossRef

76.

Nesta B, Spraggon G, Alteri C, et al.: FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. MBio 2012, 3.

77.

Roberts JA, Kaack MB, Baskin G, et al. Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein. J Urol. 2004;171:1682–5.PubMedCrossRef

78.

Alteri CJ, Smith SN, Mobley HL. Fitness of Escherichia coli during urinary tract infection requires gluconeogenesis and the TCA cycle. PLoS Pathog. 2009;5:e1000448.PubMedCrossRef

79.

Donovan GT, Norton JP, Bower JM, Mulvey MA. Adenylate cyclase and the cyclic AMP receptor protein modulate stress resistance and virulence capacity of uropathogenic Escherichia coli. Infect Immun. 2013;81:249–58.PubMedCrossRef

80.

Torres AG, Redford P, Welch RA, Payne SM. TonB-dependent systems of uropathogenic Escherichia coli: aerobactin and heme transport and TonB are required for virulence in the mouse. Infect Immun. 2001;69:6179–85.PubMedCrossRef

81.

Henderson JP, Crowley JR, Pinkner JS, et al. Quantitative metabolomics reveals an epigenetic blueprint for iron acquisition in uropathogenic Escherichia coli. PLoS Pathog. 2009;5:e1000305.PubMedCrossRef

82.

Garcia EC, Brumbaugh AR, Mobley HL. Redundancy and specificity of Escherichia coli iron acquisition systems during urinary tract infection. Infect Immun. 2011;79:1225–35.PubMedCrossRef

83.

Russo TA, McFadden CD, Carlino-MacDonald UB, et al. The siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate. Infect Immun. 2003;71:7164–9.PubMedCrossRef

84.

Durant L, Metais A, Soulama-Mouze C, et al. Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli. Infect Immun. 2007;75:1916–25.PubMedCrossRef

85.

Chaturvedi KS, Hung CS, Crowley JR, et al. The siderophore yersiniabactin binds copper to protect pathogens during infection. Nat Chem Biol. 2012;8:731–6.PubMedCrossRef

86.

Stock AM, Robinson VL, Goudreau PN. Two-component signal transduction. Annu Rev Biochem. 2000;69:183–215.PubMedCrossRef

87.

Kostakioti M, Hadjifrangiskou M, Pinkner JS, Hultgren SJ. QseC-mediated dephosphorylation of QseB is required for expression of genes associated with virulence in uropathogenic Escherichia coli. Mol Microbiol. 2009;73:1020–31.PubMedCrossRef

88.

Kostakioti M, Hadjifrangiskou M, Cusumano CK, et al. Distinguishing the contribution of type 1 pili from that of other QseB-misregulated factors when QseC is absent during urinary tract infection. Infect Immun. 2012;80:2826–34.PubMedCrossRef

89.

• Hadjifrangiskou M, Kostakioti M, Chen SL, et al. A central metabolic circuit controlled by QseC in pathogenic Escherichia coli. Mol Microbiol. 2011;80:1516–29. This paper links both virulence and metabolism of UPEC with one two-component system and suggests the potential for using this system as a new target for antimicrobials.PubMedCrossRef

90.

Debnath I, Norton JP, Barber AE, et al. The Cpx stress response system potentiates the fitness and virulence of uropathogenic Escherichia coli. Infect Immun. 2013;81:1450–9.PubMedCrossRef

91.

Hung DL, Raivio TL, Jones CH, et al. Cpx signaling pathway monitors biogenesis and affects assembly and expression of P pili. EMBO J. 2001;20:1508–18.PubMedCrossRef

92.

Hernday AD, Braaten BA, Broitman-Maduro G, et al. Regulation of the pap epigenetic switch by CpxAR: phosphorylated CpxR inhibits transition to the phase ON state by competition with Lrp. Mol Cell. 2004;16:537–47.PubMed

93.

Winberg J, Mollby R, Bergstrom J, et al. The PapG-adhesin at the tip of P-fimbriae provides Escherichia coli with a competitive edge in experimental bladder infections of cynomolgus monkeys. J Exp Med. 1995;182:1695–702.PubMedCrossRef

94.

Lane MC, Mobley HL. Role of P-fimbrial-mediated adherence in pyelonephritis and persistence of uropathogenic Escherichia coli (UPEC) in the mammalian kidney. Kidney Int. 2007;72:19–25.PubMedCrossRef

95.

Schwan WR, Lee JL, Lenard FA, et al. Osmolarity and pH growth conditions regulate fim gene transcription and type 1 pilus expression in uropathogenic Escherichia coli. Infect Immun. 2002;70:1391–402.PubMedCrossRef

96.

Rentschler AE, Lovrich SD, Fitton R, et al. OmpR regulation of the uropathogenic Escherichia coli fimB gene in an acidic/high osmolality environment. Microbiology. 2013;159:316–27.PubMedCrossRef

97.

Storz G, Imlay JA. Oxidative stress. Curr Opin Microbiol. 1999;2:188–94.PubMedCrossRef

98.

Hryckowian AJ, Welch RA. RpoS contributes to phagocyte oxidase-mediated stress resistance during urinary tract infection by Escherichia coli CFT073. MBio. 2013;4:e00023–00013.PubMedCrossRef

99.

Lundberg JO, Ehren I, Jansson O, et al. Elevated nitric oxide in the urinary bladder in infectious and noninfectious cystitis. Urology. 1996;48:700–2.PubMedCrossRef

100.

Poljakovic M, Svensson ML, Svanborg C, et al. Escherichia coli-induced inducible nitric oxide synthase and cyclooxygenase expression in the mouse bladder and kidney. Kidney Int. 2001;59:893–904.PubMedCrossRef

101.

Bower JM, Mulvey MA. Polyamine-mediated resistance of uropathogenic Escherichia coli to nitrosative stress. J Bacteriol. 2006;188:928–33.PubMedCrossRef

102.

Lewis K. Persister cells. Annu Rev Microbiol. 2010;64:357–72.PubMedCrossRef

103.

• Norton JP, Mulvey MA. Toxin-antitoxin systems are important for niche-specific colonization and stress resistance of uropathogenic Escherichia coli. PLoS Pathog. 2012;8:e1002954. This work identifies several toxin–antitoxin pairs as being important for stress resistance and bladder and kidney persistence in UPEC.PubMedCrossRef

Title: From Physiology to Pharmacy: Developments in the Pathogenesis and Treatment of Recurrent Urinary Tract Infections
Authors: Jennifer A. Silverman
Henry L. Schreiber IV
Thomas M. Hooton
Scott J. Hultgren
Publication date: 01-10-2013
Publisher: Springer US
Published in: Current Urology Reports / Issue 5/2013
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-013-0354-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

From Physiology to Pharmacy: Developments in the Pathogenesis and Treatment of Recurrent Urinary Tract Infections

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

Critical Evaluation of Modified Templates and Current Trends in Retroperitoneal Lymph Node Dissection

Urodynamics: Examining the Current Role of UDS Testing. What is the Role of Urodynamic Testing in Light of Recent AUA Urodynamics and Overactive Bladder Guidelines and the VALUE Study?

Contemporary Management of Stage I and II Seminoma

Current Recommendations for Bladder Instillation Therapy in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome

Myofascial Trigger Points of the Pelvic Floor: Associations with Urological Pain Syndromes and Treatment Strategies Including Injection Therapy

Management Options for Women with Uterine Prolapse Interested in Uterine Preservation